



## **ISPOR RUSSIA HTA Chapter Annual Report**

**2012**

TO:

Board of Directors

International Society for Pharmacoeconomics and Outcomes Research  
3100 Princeton Pike, Suite 3E  
Lawrenceville, NJ 08648 USA

PREPARED BY:

**VITALY OMELYANOVSKIY, MD, PhD, DSc, PROFESSOR**

ISPOR Russia HTA Chapter

**Moscow, Russia**

Tel: (+7-499) 245-3807

Email: vvo@hta-rus.ru, maksimova@hta-rus.ru

### **Background:**

The ISPOR Russia HTA Chapter was approved in April 2011. The chapter has 180 members.

The current leadership of the ISPOR Russia HTA Chapter is comprised of the following:

#### **President**

**Vitaly Omelianovsky, MD, PhD, DSc, Professor**

Chairman of the Board of the Non-profit Autonomous Organization “National Center for Health Technology Assessment” (NCHTA), Director of the Center for Health Technology Assessment of the Presidential Academy of National Economy and Public Administration

#### **Vice President**

**Maria Avksentiyeva MD, PhD, DSc, Professor**

Head of Department, Non-profit Autonomous Organization “National Center for Health Technology Assessment” (NCHTA)

#### **Executive Director**

**Ludmila Maksimova, PhD**, Head Department, Non-profit Autonomous Organization “National Center for Health Technology Assessment” (NCHTA)

For more information on the ISPOR Russia HTA Chapter, please visit the ISPOR Regional Chapter website at [http://www.ispor.org/regional\\_chapters/Russia-HTA/index.asp](http://www.ispor.org/regional_chapters/Russia-HTA/index.asp) and [www.hta-rus.ru](http://www.hta-rus.ru)

## ISPOR Russia HTA Chapter Annual Report – BY ACTIVITY

*The ISPOR Russia HTA Chapter has successfully developed or facilitated the following activities:*

### SCIENTIFIC /EDUCATIONAL ACTIVITIES:

#### 1. Publications:

The Chapter members published 30 scientific articles in professional journals:

- **P.M. Khailov.** Placebo and Evidence-Based Medicine. Medical Technologies. Assessment and Selection, 2012, #1(7), pp. 10-16.
- **M.V. Sura, S.V. Goryajnov, M.V. Avxentyeva, V.V. Omelyanovskiy.** Pharmacoeconomic Analysis of Pazopanib Therapy for Patients with Generalized Renal Cell Cancer. Medical Technologies. Assessment and Selection, 2012, #1(7), pp. 17-23.
- **M.V. Sura, V.V. Omelyanovskiy.** Procedure for Development of Formulary Lists Using Automated System “Dossier”. Medical Technologies. Assessment and Selection, 2012, #1(7), pp. 24-31.
- **V.V. Omelyanovsky, M.V. Avxentyeva.** Preconditions and Prospects for the Establishment of National Institutional System for Health Technology Assessment in Russia. Medical Technologies. Assessment and Selection, 2012, #1(7), pp. 54-61.
- **L.V. Maksimova, V.V. Omelyanovskiy.** International Experience of Interaction between Agencies for Health Technology Assessment and Decision-Makers in Health. Medical Technologies. Assessment and Selection, 2012, #1(7), pp. 79-84.
- **N.A. Zorin.** Quality Assessment of Scientific Publications (part II). Medical Technologies. Assessment and Selection, 2012, #1(7), pp. 85-93.
- **T.V. Kulinchik.** Pharmacological Thinking at the Patient Bed. Medical Technologies. Assessment and Selection, 2012, #1(7), pp. 98-99.
- **O.U. Rebrova.** Clinical Studies: Measures of Efficacy of Medical Technologies that Affect Time to Event. Medical Technologies. Assessment and Selection, 2012, #2(8), pp.10-15.
- **E.V. Derkach, V.I. Ignatieva, V.I. Shirokorad, V.V. Omelyanovskiy, M.V. Avxentyeva, N.D. Sveshnikova.** Social and Economic Burden of Prostate Cancer in Russia. Medical Technologies. Assessment and Selection, 2012, #2(8), pp. 34-45.
- **I.G. Rusakov., O.I. Ivakhnenko, N.S. Andreeva, S.V. Goryajnov, N.D. Sveshnikova.** Comparative Clinical and Economic Evaluation of Alternative Second-Line Therapies in Patients with Metastatic Hormone-Refractory Prostate Cancer Progressing after Initial Chemotherapy with Docetaxel. Medical Technologies. Assessment and Selection, 2012, #2(8), pp. 46-56.
- **V.I. Ignatyeva, E.V. Derkach, V.V. Omelyanovskiy, M.V. Avxentyeva.** Methodological Problems of Evaluating the Economic Burden of Malignant Tumors in Russia. Medical Technologies. Assessment and Selection, 2012, #2(8), pp.79-86.
- **O. Yu. Rebrova.** Description of Statistical Analysis in Original Publications. Common Errors. Medical Technologies. Assessment and Choice, Special Issue, 2012, pp. 27-30.
- **Khachatryan N.N., Evseev E.A., Omelyanovsky V.V., Chupalov M.O.** Modern Methods of Preventing Postoperative Complications of Abdominal Surgery. Medical Technologies.

- Assessment and Selection, 2012, #3(9), pp.26-32.
- **Vlassov V.V., Rebrova O.Yu.** Criteria for Population Efficacy of Medical Technologies. Medical Technologies. Assessment and Selection, 2012, #3(9), pp.33-41.
  - **Oskina E.A., Zhestkov A.V., Sirotko I.I., Sivakova O.V.** Methodological and Practical Aspects of Assessing the Direct Medical Costs of Pneumonia in a Single Region. Medical Technologies. Assessment and Selection, 2012, #3(9), pp. 42-51.
  - **Maximova L.V.** International Cooperation in Health Technology Assessment. Medical Technologies. Assessment and Selection, 2012, #3(9), pp. 68-74.
  - **Fedyayeva V.K.** Establishing Effective Communication with Decision-Makers. Medical Technologies. Assessment and Selection, 2012, #3(9), pp.75-80.
  - **Gerasimova K.V., Sychev D.A.** Clinical Pharmacogenetics: a Historical Overview. Medical Technologies. Assessment and Choice, 2012, #4(10), pp.87-94.
  - **Andreeva N. S., Rebrova O. Y., Zorin N. A., Avxentyeva M. V., Omelyanovskiy V. V.** Systems for Assessing the Reliability of Scientific Evidence and the Soundness of Guidelines: Comparison and Prospects for Unification. Medical Technologies. Assessment and Choice, 2012, #4(10), pp. 10-24.
  - **Pyadushkina E. A., Gerasimova K. V., Omelyanovsky V. V., Avxentyeva M. V., Krysanov I. S.** Pharmacoeconomic Analysis of Antiplatelet Therapy with Ticagrelor and Clopidogrel for Preventing Vascular Events and Death in Patients with Acute Coronary Syndrome. Medical Technologies. Assessment and Choice, 2012, #4(10), pp. 35-45.
  - **Omelyanovsky V. V., Avxentyeva M. V., Krysanov I. S., Ivahnenko O. I., Khaylov P. M.** Comparative Clinical and Economic Evaluation of Prostate Cancer Hormone Therapy with Gonadotropin-Releasing Hormone Analogues (Leuprorelin, Goserelin, Triptorelin). Medical Technologies. Assessment and Choice, 2012, #4(10), pp. 52-58.
  - **Avxentyeva M. V., Chupin A. V.** Comparative Pharmacoeconomic Analysis of Prostanoids for Peripheral Arterial Occlusive Disease. Medical Technologies. Assessment and Choice, 2012, #4(10), pp. 59-63.
  - **Zorin N. A.** «One Cannot Harness a Horse in the Same Cart as a Tender Doe». Medical Technologies. Assessment and Choice, 2012, #4(10), pp. 85-90.
  - **E.A. Pyadushkina, K.V. Gerasimova, S.V. Goryajnov, V.V. Omelyanovskiy, M.V. Avxentyeva, I. S. Krysanov.** Comparative pharmacoeconomic analysis of application of Bonviva (ibandronat) for the purpose of prevention of fractures in patients with post menopause syndrome. Contemporary Rheumatology, #4 2012, pp.89-96.
  - **Krysanov I.S., Margieva A.V., Andreeva N.S., V.V. Omelyanovskiy, Avxentyeva M.V.** Comparative Pharmacoeconomic analysis of application of Roflumilast in complex therapy of surgical obstructive pulmonary disease. Atmosphere. Pulmonology and Allergology, 2012, #2, pp. 28-35.
  - **Kulinchik T.V., Rebrova O. Yu., Margieva A.V., Avxentyeva M.V., Voskresensky O. Yu., Petrova N.V., Reino E.V.** Clinical efficacy and safety of primary prevention of thrombotic complications after orthopedic surgeries. Bulletin of Traumatology and orthopedics named after N.N. Pirogov, 2012, @3, pp. 39-46.
  - **T. E. Komleva, O.Yu. Rebrova, S.K. Daurov, A.A. Marianovskiy.** Method for detecting the rate of degenerative alterations of intervertebral discs during computer analysis of digital MR tomograms. Bulletin of new medical technologies, 2012, Volume. XIX, №1, pp. 195-197.
  - **O.Yu. Rebrova.** Indirect Comparisons in Clinical and Economic Analysis. Hematology and Transfusiology, 2012, №3 (Appendix), p. 22.
  - **O.Yu. Rebrova.** Problems of quality control of the Russian scientific medical publications.

Armenian medical abstract journal (Journal of Evidence-based medicine), 2012, #9, pp. 203-207.

- **M.V. Avksentyeva.** Pharmacoeconomics in oncology: factors, state and prospects of standardization of oncology care. Russia edition of The Malignant Tumors journal, 2012, #2, pp. 35-37.
  - **M.V. Avxentyeva, I.S. Krysanov, A.V. Chupin.** Pharmacoeconomic aspects of therapy of obliterating diseases of peripheral arteries of lower extremities. Angiology and vascular surgery, 2012, #4, pp. 89-96.
2. Seminars and Trainings:
- Educational seminars on evidence-based medicine and pharmacoeconomic - in 5 Russian regions.
  - 4 Trainings on ABC/VEN/DDD analysis - an HTA toolkit for evaluating drug purchases and assessing regional reimbursed drug lists and formularies.
  - 5 Trainings on Dossier program ([www.docie.ru](http://www.docie.ru)) – an HTA toolkit for forming regional reimbursement lists and programs.
  - 4 Trainings on PharmEc automated system for multilevel multidisciplinary assessment of formulary and positive lists at different levels of the healthcare system. ([www.pharmec.docie.ru](http://www.pharmec.docie.ru))
  - ISPOR Russia HTA Chapter together with Market Access Consulting continued providing Market Access trainings for representatives of pharmaceutical companies and health care decision-makers. 4 Market Access trainings were conducted by the ISPOR Russia HTA Chapter in 2012.
  - 3 Trainings on HTA for healthcare experts, officials and company representatives.
3. Presentations and Participation in Round tables/Special Sessions at Major Medical Conferences and Congresses: Russia ISPOR HTA Chapter members made presentations, participated in special sessions and round tables at 22 major domestic and international health conferences and congresses in Russia and abroad.
- Special Sessions and Roundtables were held within the framework of a number of important conferences, including
    - o 16<sup>th</sup> Pediatrics Congress with International participation, Moscow, February 24-27, 2012;
    - o 11<sup>th</sup> International Conference Artificial Intelligence and Soft Computing, Zakopane, May 3, 2012;
    - o All Russia conference “Topical Problems of Clinical Pharmacology and Drug Supply, St. Petersburg, May 15-16, 2012;
    - o ISPOR 17<sup>th</sup> Annual International Meeting, Washington, DC, May 2012;
    - o International Forum Europe and Russia. Harmonization Vector. 1<sup>st</sup> Session, Riga, June 2012
    - o Russian Hematology Congress, Moscow, July 2-4, 2012;
    - o 7<sup>th</sup> Annual Congress of Specialists in Perinatal Medicine, Moscow, September 24-25, 2012;
    - o International conference Continuous Medical Education and Quality of Medical Care, Moscow, September 28, 2012;
    - o 7<sup>th</sup> International Congress “Rational Pharmacotherapy 2012, St. Petersburg, October 11-13, 2012;
    - o 22<sup>nd</sup> National Congress on Respiratory Diseases, Moscow, October 23-26, 2012;
    - o ISPOR 15th Annual European ISPOR Congress on 3-7 November 2012 in Berlin (Germany).
    - o 15<sup>th</sup> Russia Oncology Congress, Moscow, November 2012
    - o International Forum Europe and Russia. Harmonization Vector. 2nd Session, Moscow, December 2012

4. Pharmacoeconomic studies: ISPOR Russia HTA Chapter completed 27 pharmacoeconomic and health economics studies covering Alcoholism, Schizophrenia, Prostate Cancer, Ovary Cancer, Kidney Cancer, Ankylosing Spondylitis, Virus Hepatitis C, Acute Coronary Syndrome, Premature Labor Prophylaxis, Psoriatic Arthritis, Lung Cancer, Breast Cancer, Rheumatoid Arthritis, Rentgenocontrast Substances, HIV, Managed Narcosis, Chronic Obstructive Pulmonary Disease, Transcutaneous Coronary Interventions and Stents, Epilepsy, Juvenile Rheumatoid Arthritis. Several studies used cost of illness and indirect comparisons methodology.

5. Development of HTA approaches

**Toolkits for assessing and compiling formularies/reimbursed drug lists, including:**

- a. **ABC/VEN/DDD analysis** – IT-based technology for evaluating hospital and regional government costs of drug purchases, assessing drug lists to confirm that drugs included in these lists are essential and vital. More than 280 Russian pharmacists, clinical pharmacologists, federal and regional health care decision-makers use ABC/VEN/DDD analysis program in their every day work.
- b. **PHARMEC** – a multi-level and interdisciplinary expert assessment of pharmaceuticals to provide support in developing reimbursement programs for regional health authorities.
- c. **Dossier program (www.docie.ru)** – a web-based value dossier preparation and submission toolkit for developing regional reimbursed drug lists and hospital formularies. It is based on online application procedure (application form includes 30 different items) and availability of electronic reference database of drugs already included in reimbursement and under review.

6. ISPOR Russia HTA Chapter members actively participated in the ISPOR 15th European Congress on 3-7 November 2012 in Berlin (Germany) with the following 15 poster presentations:

- PHARMACOECONOMIC ANALYSIS OF ROFLUMILAST FOR TREATMENT OF ADULT PATIENTS WITH SEVERE-TO-VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

**Margieva A, Omelyanovsky V, Avxentyeva M, Krysanov I, Zorin N, Andreyeva N**

- COST OF LONG-ACTING RISPERIDONE INJECTION VERSUS LONG-ACTING PALIPERIDONE PALMITATE IN PATIENTS WITH SCHIZOPHRENIA IN RUSSIA

**Omelyanovsky V, Avxentyeva M, Ivakhnenko O, Khailov P, Tsfasman F, Krysanov I, Zorin N**

- ECONOMIC BURDEN OF MELANOMA IN RUSSIA

**Ignateva V, Derkach E, Omelyanovsky V, Avxentyeva M**

- ECONOMIC BURDEN OF PROSTATE CANCER IN RUSSIA

**Ignateva V, Derkach E, Omelyanovsky V, Avxentyeva M, Sveshnikova N, Grabareva D**

- PHARMACOECONOMIC ANALYSIS OF THE PROSTATE CANCER THERAPY WITH GONADOTROPIN-RELEASING HORMONE ANALOGUES: LEUPRORELIN, GOSERELIN, TRIPTORELIN

**Omelyanovsky V, Avxentyeva M, Ivakhnenko O, Khailov P, Krysanov I, Maksimova L**

- ECONOMIC BURDEN OF JUVENILE IDIOPATHIC ARTHRITIS IN RUSSIA

**Derkach E, Omelyanovsky V, Avxentyeva M, Ivakhnenko O, Ignateva V**

- COST-MIMIMIZATION ANALYSIS OF PAZOPANIB VERSUS SUNITINIB, SORAFENIB AND BEVACIZUMAB\_ INTERFERON á-2A FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

**Sura M, Goryaynov S, Avxentyeva M, Omelyanovsky V**

- THE COSTS OF UNINTENDED PREGNANCY IN RUSSIA

**Ignateva V, Krysanov I, Khachatryan G**

- CLINICAL EFFICACY AND COST-EFFECTIVENESS OF HUMAN RECOMBINANT INTERFERON-2B IN NEONATAL INFECTIONS

**Soldatova I, Pankratyeva L**

- BURDEN OF EARLY-ONSET NEONATAL SEPSIS IN THE RUSSIAN FEDERATION

**Soldatova I, Pankratyeva L, Avxentyeva M, Omelyanovsky V**

- COST-EFFECTIVENESS OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA IN RUSSIA

**Omelyanovsky V, Avxentyeva M, Ivakhnenko O, Khailov P, Krysanov I, Tsfasman F**

- COST ANALYSIS OF TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME IN RUSSIA

**Pyadushkina E, Gerasimova K, Avxentyeva M, Krysanov I**

- THE PHARMACOECONOMIC ANALYSIS OF ILOPROST IN CRITICAL LIMB ISCHEMIA

**Avxentyeva M1, Krysanov I1, Chupin A2**

- NEW OPTIONS FOR SECOND-LINE TREATMENT OF HORMONE REFRACTORY METASTATIC PROSTATE CANCER^ COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE AND CABAZITACXEL COMPARED WITH MITOXANTRONE

**Ivakhnenko O., Andreeva N., Goryajnov, Sveshnikova N., Grabareva D.**

- CLINICAL EFFICACY AND COST-EFFECTIVENESS OF ADDITIONAL IMMUNOTHERAPY IN EARLY-ONSET NEONATAL INFECTIONS

**Soldatova I, Pankratyeva L, Degtyareva M., Volodin N.**

7. Participation in ISPOR short courses

More than 70 ISPOR Russia HTA Chapter members participated in 8 different short courses organized within the framework of the 15th ISPOR Annual European ISPOR Congress on 3-7 November 2012 in Berlin (Germany).

8. Participation in review of abstract presentations

Three ISPOR Russia HTA Chapter members acted as reviewers of abstract presentations for the ISPOR 15th Annual European Congress on 3-7 November 2012 in Berlin (Germany).

### **POLICY-RELATED ACTIVITIES:**

ISPOR Russia HTA Chapter developed and implemented the following HTA methods, instruments and documents:

- **National Institutional System of Health Technology Assessment in the Russian Federation (NISOMT)** - a strategic initiative directed at supporting informed, timely and effective decision-making and effective innovations management in health care of Russia.
- **First in Russia International Conference on Health Technology Assessment:** International Experience and Prospects of Implementation in Russia, May 21, 2012. Thirteen leading international experts in HTA made presentations at the conference. **The conference was participated by 300 healthcare officials, experts, decision-makers, medical community representatives from different Russian regions.**
- **Pilot project with the World Bank and the Federal Mandatory Insurance Fund on introducing hospital funding system based on DRG**
- **Roundtable with NICE International “HTA, clinical guidelines and quality standards: NICE experience and prospects of its implementation in Russia” which took place in Moscow, on December 12, 2012.** The Roundtable was participated by healthcare officials, experts and company representatives.

### **CHAPTER MEETINGS and WORKSHOPS:**

- ISPOR Russia HTA Chapter organized a Roundtable on risk-sharing in oncology within the framework of ISPOR 17<sup>th</sup> Annual International Meeting in Washington, DC, May 2012.
  - ISPOR Russia organized **three meetings** at the 15<sup>th</sup> Annual European Congress in Berlin, November 3-7, 2012:
    - Conjoint Forum of ISPOR RUSSIA HTA, UKRAINE, BELARUS, KAZAKHSTAN AND ARMENIA REGIONAL CHAPTERS, November 5, 2012.
    - **ROUNDTABLE” Health Technology Assessment of Pharmaceutical Drugs and Medical Devices: International Experience and Possibilities of Its Practical Application in Russia and Neighboring Countries”,** November 6, 2012.
    - **SEMINAR «Implementing risk-sharing models in oncology»,** November 5, 2012
2. ISPOR Russia HTA Chapter together with the Council of Federation organized the following three meetings:
- Seminar on Ways of Decreasing the Level of Incidence of Virus Hepatitis C were held in a number of Russian regions, including Sverdlovsk, Murmansk, Nizhny Novgorod, Rostov as well as Siberian Federal District. 300 people participated in the meetings.
  - Roundtable on Issues of Work Safety for Medical Personnel: problems and Solutions.
  - Roundtable on Consequences and Costs of Prevention of Bacterial Resistance in Russia.

### **MEMBERSHIP DEVELOPMENT:**

ISPOR Russia HTA Chapter has added 50 members since the end of 2011. The total number of Chapter members is over 180.

## **Upcoming Activities for ISPOR Russia HTA Chapter 2013**

## Tentative Agenda

Date	Activities
February	One full day structured brainstorming session "Approaches of Prevention of Bacterial Resistance in Russia: regional and federal levels. Financing and Regulation. Role of the State and Expert Society
February	Special Session on HTA within the framework of CIS Pharmaceutical Forum, Moscow, February 5-6, 2013
March	Developing HTA guidelines and methodology
May	Organizing 2nd <sup>s</sup> International HTA conference in Moscow to promote HTA methodology in Russia and institutionalize HTA in the decision-making process.
April	Internal chapter meetings, Moscow.
May	Chapter leadership elections
November	Co-organizing an HTA conjoint forum during with Belarus, Ukraine, Kazakhstan and Armenia Chapters during the 16 <sup>th</sup> ISPOR Annual European Meeting, Dublin, Ireland
February -December	Evidence-based medicine, Pharmacoeconomics and HTA Trainings for Russian regional health care officials and experts
February -June	Implementing HTA Elements on the federal and regional levels. Organizing meetings with regional ministers of Health in order to promote and implement HTA in Russia's regions.
February-December	Trainings for the staff of the regional ministries of health on implementing elements of HTA in their respective regions.